publication venue for
- Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis 2024
- Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor). 14:441-451. 2024
- Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. 13:1889-1890. 2023
- Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. 13:1891-1892. 2023
- Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. 13:867-889. 2023
- A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians. 12:2715-2730. 2022
- Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE). 12:1417-1430. 2022
- Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. 12:1073-1089. 2022
- Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. 12:253-265. 2022
- Psoriasis Prevalence and Severity by Expert Elicitation. 11:1053-1064. 2021
- Clinical Goals and Barriers to Effective Psoriasis Care. 9:5-18. 2019
- Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. 8:17-32. 2018